Patient Subgroup Analysis of Quality-of-Life Outcomes in Checkmate 205, a Phase 2 Study of Nivolumab in Patients with Classical Hodgkin Lymphoma

被引：0
|
作者：
Engert, Andreas [1 ]
Taylor, Fiona [2 ]
Bennett, Bryan [3 ]
Hirji, Ishan [4 ]
Cocks, Kim [3 ]
McDonald, Jeffrey [2 ]
Mann, Erin [2 ]
Kato, Kazunobu [4 ]
Cella, David [5 ]
机构：
[1] Univ Hosp Cologne, Cologne, Germany
[2] Adelphi Values, Boston, MA USA
[3] Adelphi Values, Bollington, England
[4] Bristol Myers Squibb Co, Princeton, NJ USA
[5] Northwestern Univ, Evanston, IL 60208 USA
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.1831.1831
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1831
引用
收藏
页数：6
相关论文
共 50 条
  • [41] Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma
    Johnston, Patrick B.
    Pinter-Brown, Lauren C.
    Warsi, Ghulam
    White, Kristen
    Ramchandren, Radhakrishnan
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2018, 7
  • [42] Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma
    Patrick B. Johnston
    Lauren C. Pinter-Brown
    Ghulam Warsi
    Kristen White
    Radhakrishnan Ramchandren
    Experimental Hematology & Oncology, 7
  • [43] Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma
    Younes, Anas
    Oki, Yasuhiro
    McLaughlin, Peter
    Copeland, Amanda R.
    Goy, Andre
    Pro, Barbara
    Feng, Lei
    Yuan, Ying
    Chuang, Hubert H.
    Macapinlac, Homer A.
    Hagemeister, Fredrick
    Romaguera, Jorge
    Samaniego, Felipe
    Fanale, Michelle A.
    Dabaja, Bouthaina Shbib
    Rodriguez, Maria A.
    Dang, Nam
    Kwak, Larry W.
    Neelapu, Sattva S.
    Fayad, Luis E.
    BLOOD, 2012, 119 (18) : 4123 - 4128
  • [44] Phase 2 Study of Frontline Brentuximab Vedotin Plus Nivolumab in Patients with Hodgkin Lymphoma Aged ≥60 Years
    Yasenchak, Christopher A.
    Bordoni, Rodolfo
    Yazbeck, Victor
    Patel-Donnelly, Dipti
    Anderson, Thomas
    Larson, Timothy
    Newhook, Trevor
    Mei, Matthew
    Ho, Linda
    Friedberg, Jonathan W.
    BLOOD, 2019, 134
  • [45] Phase 2 Study of Frontline Brentuximab Vedotin Plus Nivolumab in Patients With Hodgkin Lymphoma Aged ≥60 Years
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (02) : 8 - 9
  • [46] Health-Related Quality of Life in Patients With Hodgkin Lymphoma: A Longitudinal Analysis of the German Hodgkin Study Group
    Kreissl, Stefanie
    Mueller, Horst
    Goergen, Helen
    Meissner, Julia
    Topp, Max
    Soekler, Martin
    Markova, Jana
    Bernhard, Jurg
    Greil, Richard
    von Tresckow, Bastian
    Behringer, Karolin
    Rueffer, Jens-Ulrich
    Flechtner, Hans-Henning
    Moestl, Michaela
    Fuchs, Michael
    Engert, Andreas
    Diehl, Volker
    Borchmann, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (25) : 2839 - +
  • [47] Nivolumab and brentuximab vedotin (BV)-based, response-adapted treatment in primary refractory patients (pts) and in pediatric pts with relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) in the phase 2 CheckMate 744 study
    Mauz-Koerholz, C.
    Leblanc, T.
    Harker-Murray, P.
    Mascarin, M.
    Michel, G.
    Cooper, S.
    Beishuizen, A.
    Leger, K. J.
    Garaventa, A.
    Buffardi, S.
    Brugieres, L.
    Kelly, K. M.
    Cole, P. D.
    Drachtman, R. A.
    Manley, T.
    Francis, S.
    Sacchi, M.
    Daw, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 161 - 162
  • [48] Sexual quality of life in Hodgkin Lymphoma: a longitudinal analysis by the German Hodgkin Study Group
    K Behringer
    H Müller
    H Görgen
    H-H Flechtner
    C Brillant
    T V Halbsguth
    I Thielen
    D A Eichenauer
    T Schober
    H Nisters-Backes
    M Fuchs
    A Engert
    P Borchmann
    British Journal of Cancer, 2013, 108 : 49 - 57
  • [49] Sexual quality of life in Hodgkin Lymphoma: a longitudinal analysis by the German Hodgkin Study Group
    Behringer, K.
    Mueller, H.
    Goergen, H.
    Flechtner, H-H
    Brillant, C.
    Halbsguth, T. V.
    Thielen, I.
    Eichenauer, D. A.
    Schober, T.
    Nisters-Backes, H.
    Fuchs, M.
    Engert, A.
    Borchmann, P.
    BRITISH JOURNAL OF CANCER, 2013, 108 (01) : 49 - 57
  • [50] Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma
    Armand, Philippe
    Janssens, Ann
    Gritti, Giuseppe
    Radford, John
    Timmerman, John
    Pinto, Antonio
    Vilchez, Santiago Mercadal
    Johnson, Peter
    Cunningham, David
    Leonard, John P.
    Rodig, Scott J.
    Martin-Regueira, Patricia
    Sumbul, Anne
    Samakoglu, Selda
    Tang, Hao
    Ansell, Stephen M.
    BLOOD, 2021, 137 (05) : 637 - 645
12345